Cargando…
179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Association for the Study of Lung Cancer. Published by Elsevier Inc. Published by Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997779/ http://dx.doi.org/10.1016/S1556-0864(21)02021-9 |
| _version_ | 1783670403764322304 |
|---|---|
| author | Pierre, C. Goter, T. Agar, C. Luzi, S. Lena, H. Guen, Y. Le Ricordel, C. |
| author_facet | Pierre, C. Goter, T. Agar, C. Luzi, S. Lena, H. Guen, Y. Le Ricordel, C. |
| author_sort | Pierre, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7997779 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | International Association for the Study of Lung Cancer. Published by Elsevier Inc. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79977792021-03-29 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center Pierre, C. Goter, T. Agar, C. Luzi, S. Lena, H. Guen, Y. Le Ricordel, C. J Thorac Oncol Advanced Nsclc International Association for the Study of Lung Cancer. Published by Elsevier Inc. Published by Elsevier Inc. 2021-04 2021-03-27 /pmc/articles/PMC7997779/ http://dx.doi.org/10.1016/S1556-0864(21)02021-9 Text en © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Advanced Nsclc Pierre, C. Goter, T. Agar, C. Luzi, S. Lena, H. Guen, Y. Le Ricordel, C. 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center |
| title | 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center |
| title_full | 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center |
| title_fullStr | 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center |
| title_full_unstemmed | 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center |
| title_short | 179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center |
| title_sort | 179p efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the covid-19 outbreak: experience from a single center |
| topic | Advanced Nsclc |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997779/ http://dx.doi.org/10.1016/S1556-0864(21)02021-9 |
| work_keys_str_mv | AT pierrec 179pefficacyandsafetyofextendedintervaldosingstrategyofimmunecheckpointinhibitorsduringthecovid19outbreakexperiencefromasinglecenter AT gotert 179pefficacyandsafetyofextendedintervaldosingstrategyofimmunecheckpointinhibitorsduringthecovid19outbreakexperiencefromasinglecenter AT agarc 179pefficacyandsafetyofextendedintervaldosingstrategyofimmunecheckpointinhibitorsduringthecovid19outbreakexperiencefromasinglecenter AT luzis 179pefficacyandsafetyofextendedintervaldosingstrategyofimmunecheckpointinhibitorsduringthecovid19outbreakexperiencefromasinglecenter AT lenah 179pefficacyandsafetyofextendedintervaldosingstrategyofimmunecheckpointinhibitorsduringthecovid19outbreakexperiencefromasinglecenter AT guenyle 179pefficacyandsafetyofextendedintervaldosingstrategyofimmunecheckpointinhibitorsduringthecovid19outbreakexperiencefromasinglecenter AT ricordelc 179pefficacyandsafetyofextendedintervaldosingstrategyofimmunecheckpointinhibitorsduringthecovid19outbreakexperiencefromasinglecenter |